Huabo Biopharm

Executive Summary

Huabo Biopharm is a private, China-based biotechnology company focused on developing innovative antibody-based biologics for oncology. Founded in 2010 and headquartered in Hangzhou, the company specializes in bispecific antibody formats and novel targets to advance next-generation cancer immunotherapies. With a mission to improve survival and quality of life for cancer patients, Huabo is currently in the Phase 1 clinical stage, leveraging its expertise in antibody engineering to address unmet medical needs. Despite limited public information on specific pipeline progress, the company's strategic focus on immuno-oncology and bispecific platforms positions it within a high-growth area of drug development. Given its early-stage nature and lack of disclosed financing or valuation data, the conviction score is moderate, reflecting the inherent risks of preclinical and Phase 1 development in a competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim data readout for lead bispecific antibody candidate40% success
• Q4 2026IND approval for second pipeline candidate60% success
• TBDStrategic partnership or licensing deal for bispecific platform30% success